Abstract

CANAGLIFLOZIN: A SGLT-2 INHIBITOR FOR THE TREATMENT OF HEART FAILURE IN TYPE-2 DIABETIC PATIENTS

Dr. Ashitha Ephrem and Maxwel Roshan Dsouza*

.

Abstract

The increased significance of DM as a cardiovascular disease (CVD) risk factor is probably brought on by the fact that DM rates are rising and its relative risk as a CVD risk factor isn't decreasing. As a new class of anti-diabetic medications for the treatment of type 2 diabetes, canagliflozin, a strong and selective sodium glucose co-transporter 2 inhibitor, canagliflozin 300 mg is currenty in trend and has direct or indirect impacts on non-glycemic parameters in addition to regulating blood sugar. Canagliflozin 300 mg, unlike several AHAs, does not cause weight gain; instead, it has a weight-reduction and average systolic and diastolic blood pressure reductions were 4.7 and 1.9 mmHg, respectively. Treatment with canagliflozin resulted in a significant decrease in blood sugar, total cholesterol, LDL cholesterol, and triglyceride levels. Canagliflozin decreased the likelihood of long-term renal function deterioration, decreased albuminuria excretion, and slowed eGFR decline. Patients with type 2 diabetes mellitus and established cardiovascular disease or at high risk of cardiovascular events who were treated with canagliflozin experienced significantly reduced rates of cardiovascular death or hospitalised HF. Canagliflozin is associated with the alleviation of cardiac stress with improvement of diastolic dysfunction and decreased left ventricle mass (LVM). Canagliflozin has demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function.

Keywords: Diabetes Mellitus, Canagliflozin, Cardiovascular disease, Heart failure.